Weak yes - which is why we need the study. However, the data we DO have shows a 92% efficacy among people without a second dose. I don't see how this is so weak we should not seriously consider it. 2/983 vs 28/1059. Durability unknown - some ppl go out to 108 days.
-
-
The non-random arm—missing dose in the real world—can give signal to stop randomized trial while not being good enough to green-light. (Part of my conceptual model here is how UK/NHS turned the kitchen sink clinical phase into randomized trials and we got dexa out of that).
-
Yep, all good points. But the data in both trials say that 1 dose doesn’t produce a potent response. So the prudent move would be to keep using 2 doses until a trial shows otherwise? If the rollout switched to 1 dose now and it didn’t work, then we’ve wasted the early supply?pic.twitter.com/5wAdSjbDGB
- Show replies
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.